Following the onset of nonarteritic anterior ischemic optic neuropathy, regular stroke workup may be necessary.
Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes.
The safety committee of the European Medicines Agency (EMA) will again study the medication, semaglutide, out of concerns ...
Semaglutide is associated with nonarteritic anterior ischemic optic neuropathy (NAION) among patients with type 2 diabetes (T2D) and those with overweight/obesity.
Pharmacovigilance Risk Assessment Committee (PRAC) has started a review of medicines containing semaglutide following ...
TUESDAY, Jan. 14, 2025 (HealthDay News) -- Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes ...
Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay ...
Findings seen for patients with type 2 diabetes during a 5-year period. (HealthDay News) — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic ...
TUESDAY, Jan. 14, 2025 (HealthDay News) -- Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback